This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Galectin Therapeutics Presents Preclinical Data On The Treatment Of Fatty Liver Disease And Fibrosis At EASL

Galectin Therapeutics Inc. (OTC: GALT), the leader in developing carbohydrate-based therapeutic compounds to inhibit galectin proteins, today announced that it presented a poster at the European Association for the Study of the Liver (EASL) Special Conference on Liver Transplantation in Lisbon, Portugal. The data show that galectin inhibitor candidate GR-MD-02 reversed fibrosis in mouse models of steatohepatitis and prevented collagen deposits in groups treated before fibrotic cells were present. The data suggest that patients with non-alcoholic steatohepatitis (NASH), also referred to as fatty liver disease, may benefit from galectin inhibition and that GR-MD-02 could drive in a reduction of steatosis, necrosis, inflammation and collagen deposits. Currently, liver transplantation is the only option for patients afflicted with liver fibrosis or cirrhosis, and many times the condition recurs in the patient’s new liver, creating the need for a safer and more efficacious treatment. The data presented provide promising evidence for advancing GR-MD-02 into clinical studies for the treatment of NASH.

“Galectin Therapeutics has previously demonstrated the robust ability of our galectin inhibitor compounds to arrest and reverse liver fibrosis in preclinical studies,” said Dr. Peter G. Traber, President, Chief Executive Officer and Chief Medical Officer, Galectin Therapeutics. “We have now expanded that data to include promising results in preclinical models of NASH, offering hope that a new treatment option could be on the horizon and expanding the potential indications for Galectin Therapeutics to pursue in the clinic. The broad effect of GR-MD-02 on all parameters of NASH liver injury, including fat deposition, liver cell death, inflammation, and fibrosis makes this a particularly attractive drug candidate.”

The data presented at EASL Special Conference highlight two carbohydrate-based galectin inhibitors, GM-CT-01 and GR-MD-02, in preclinical mouse models of steatohepatitis. Mice are injected with streptozotocin to induce diabetes and then fed a high fat diet. Subsequently, these mice develop fatty liver (steatosis), liver cell death, inflammation between 5 weeks of age, and then, fibrosis by 9 weeks of age. To assess the ability of galectin inhibitors to prevent or reduce fibrosis, mice were separated into early or late treatment groups. Early treatment groups began receiving either GM-CT-01 or GR-MD-02 twice daily at 6 weeks of age, or before fibrosis is evident, until 9 weeks of age. Late treatment groups received either GM-CT-01 or GR-MD-02 twice daily at 9 weeks of age, or when fibrosis is established, until 12 weeks of age. GR-MD-02 demonstrated greater improvements in steatosis, hepatocellular degeneration and inflammation. In the early treatment group, GR-MD-02 prevented the development of collagen deposition, or fibrosis, and was able to completely reverse fibrosis in the late treatment group back to levels of normal mice. GM-CT-01 did show a moderate effect on reducing collagen deposition. Importantly, GR-MD-02 was able to reverse steatohepatitis and fibrosis without having an effect on the diabetic condition of the mice. To view the complete poster presentation, please go to the Galectin Therapeutics’ web site at

About NASH

NASH is a common disease of the liver, affecting 9 to 15 million people in the United States and is characterized by the presence of fat in the liver along with inflammation and damage in people who drink little or no alcohol. Over time, patients with NASH can develop fibrosis, or scarring of the liver, that can lead to cirrhosis, a severe liver disease where transplantation is the only current treatment available. Galectin Therapeutics is developing drug candidates as an alternative to transplantation and lead candidates have reversed fibrosis in preclinical disease models.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,888.35 +168.43 0.95%
S&P 500 2,102.63 +22.22 1.07%
NASDAQ 5,156.3060 +47.64 0.93%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs